A recent study suggests that individuals who come off popular GLP-1 drugs like Mounjaro or Wegovy tend to recover shed pounds much more quickly than those who end conventional lifestyle programs.
Research printed in a major health publication demonstrates that while obese individuals frequently drop substantial amounts of their body weight while on the medication, the weight comes back at an estimated rate of nearly a kilo each month after stopping.
"Individuals using these treatments need to be informed of the risk of rapid rebound weight gain when the treatment is stopped," stated expert Dr. Susan Jebb.
Such speed of regain suggests a reversion to pre-treatment weight within about a year and a half.
Analyzing Treatments
The research, which reviewed 37 of studies involving thousands of patients, contrasted the effects of these new drugs with other pills.
Scientists point out that individuals who lose weight through dieting usually experience a more gradual creep back—perhaps 100 grams monthly—once they finish.
Understanding the Rapid Regain
Doctors suggest the mechanism of the drugs is key to understanding the accelerated rebound.
GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which controls appetite.
"Artificially providing GLP-1 levels far above than the body's typical production may cause the system to produce less of its own natural GLP-1, and could diminish sensitivity to its effects," said Dr. Adam Collins, a nutrition researcher.
"Stopping of this medication leads to appetite is uncontrolled, making binge eating far more likely."
A Chronic Disease?
Medical guidelines recommend the jabs for people with obesity-related health risks, accompanied by prescribed diet and exercise modifications.
A number of clinicians say that, given the likelihood of weight regain, the therapy is often ongoing.
This perspective is echoed by drug manufacturers, who state that the findings "highlight the long-term character of excess weight," comparing it to managing conditions like hypertension.
User Experiences
People who have stopped the medication describe a intense resurgence of cravings.
"It was like a switch that goes on and I was suddenly starving," described an individual.
The struggle is exacerbated if individuals have not developed lasting lifestyle or habit modifications during treatment.
Widespread Adoption
Survey data indicate that a significant number of people in the UK have used these injections in the last 12 months, with desire remaining high.
- Use is higher among women compared to males.
- The 40s and 50s age group shows the highest usage rates.
- A large proportion access the drugs through private prescriptions rather than public health services.
Finally, experts stress that while GLP-1 drugs are potent tools for weight loss, they are not a standalone solution and maintained weight loss hinges on combined behavioural support.
